Skip to content

Large Language Models to Aid Gynecological Oncology Treatment

Medical Students and Their Perception of Large Language Models (LLMs) in Gynecologic Oncology

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06865534
Acronym
EASING
Enrollment
70
Registered
2025-03-10
Start date
2026-05-22
Completion date
2026-08-06
Last updated
2026-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

large language models, clinical decision support, gynecological oncology

Brief summary

This trial aims to assess the impact of providing medical students with access to large language models, in comparison to treatment guideline pdfs, on treatment concordance with a conventional multidisciplinary tumor board

Detailed description

Advanced artificial intelligence (AI) technologies, particularly large language models such as OpenAI's ChatGPT, hold significant potential for enhancing medical decision-making. While ChatGPT was not specifically designed for medical applications, it has shown utility in various healthcare scenarios, including answering patient inquiries, drafting medical documentation, and aiding clinical consultations. Despite these advancements, its role in supporting treatment decision-making-particularly in complex oncological cases-remains underexplored. Treatment decision-making in gynecological oncology is a multifaceted process that integrates evidence-based guidelines, tumor biology, patient-specific factors, and clinical expertise. AI tools like ChatGPT could potentially assist in synthesizing relevant guideline-based recommendations, improving decision accuracy, and facilitating more efficient clinical workflows. However, ChatGPT is not specifically tailored for oncological treatment decisions and lacks comprehensive validation in this domain. Additionally, it may generate misinformation or plausible-sounding but inaccurate recommendations, which could impact clinical judgment. Therefore, understanding how medical professionals, including students and early-career physicians, interact with such AI tools is essential before broader integration into clinical practice. Locally deployable models, such as Llama, enable secure, on-premise usage while retrieval-augmented generation ensures guideline-compliant recommendations. This study will investigate the impact of language models on treatment decision support for medical students managing gynecological oncology cases. This is a crossover study, where participants will be randomized into two groups. All participants begin with access to ChatGPT for two vignettes. They then proceed with two cases using either a locally deployed language model, followed by two cases relying on guideline PDFs, or vice versa. Each participant will analyze clinical cases, propose treatment plans, and rate their confidence in their decisions and decision support system usability. This study aims to provide insights into the potential benefits and limitations of integrating AI tools like ChatGPT into oncological treatment decision-making.

Interventions

OTHERLocal language model

Group will be given access to local language model first after using ChatGPT and then will get access to pdf file

OTHERGuideline pdf

Group will be given access to pdf file after ChatGPT and then to a local language model

Sponsors

Philipps University Marburg
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

\- Medical students having started with clinical subjects

Exclusion criteria

\- Not being a medical student

Design outcomes

Primary

MeasureTime frameDescription
Treatment concordance with tumor board decisionsdirectly (within 10 minutes) after InterventionParticipants in each group select treatment modalities for case vignettes

Secondary

MeasureTime frameDescription
Treatment confidencedirectly (within 10 minutes) after InterventionFor each case participants will be asked for their treatment confidence (VAS 0-10). The mean score will be compared between decision support groups.
Time spent for treatment decisiondirectly (within 10 minutes) after InterventionTime (in seconds) participants spend per case between the decision support groups will be compared.

Countries

Germany

Contacts

PRINCIPAL_INVESTIGATORSebastian Griewing, MD PhD

Philipps University Marburg

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 20, 2026